<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Unveiling the antiglioblastoma potential of harmicens, harmine and ferrocene hybrids</dc:title><dc:creator>Poje,	Goran	(Avtor)
	</dc:creator><dc:creator>Šakić,	Davor	(Avtor)
	</dc:creator><dc:creator>Marinovich,	Marina	(Avtor)
	</dc:creator><dc:creator>You,	Jiangyang	(Avtor)
	</dc:creator><dc:creator>Tarpley,	Michael	(Avtor)
	</dc:creator><dc:creator>Williams,	Kevin P.	(Avtor)
	</dc:creator><dc:creator>Golub,	Nikolina	(Avtor)
	</dc:creator><dc:creator>Dernovšek,	Jaka	(Avtor)
	</dc:creator><dc:creator>Tomašič,	Tihomir	(Avtor)
	</dc:creator><dc:creator>Bešić,	Erim	(Avtor)
	</dc:creator><dc:creator>Rajić,	Zrinka	(Avtor)
	</dc:creator><dc:subject>harmine</dc:subject><dc:subject>β-carboline</dc:subject><dc:subject>ferrocene</dc:subject><dc:subject>hybrid compounds</dc:subject><dc:subject>antiproliferative activity</dc:subject><dc:subject>glioblastoma multiforme</dc:subject><dc:subject>Hsp90</dc:subject><dc:subject>DYRK1A</dc:subject><dc:subject>antioxidant activity</dc:subject><dc:subject>EPR spectroscopy</dc:subject><dc:description>The poor prognosis of glioblastoma multiforme, inadequate treatment options, and growing drug resistance urge the need to find new effective agents. Due to the significant anti-cancer potential of harmicens, hybrid compounds which comprise harmine/β-carboline and ferrocene moiety, we investigated their antiglioblastoma potential in vitro and mechanism of action (inhibition of DYRK1A, Hsp90, anti-oxidative activity). The results have shown that triazole-type harmicens, namely 5, with a ferrocene moiety in C-3 position of the β-carboline ring (IC$_{50}$ = 3.7 ± 0.1 µmol L$^{–1}$, SI = 12.6) and., the C-6 substituted harmicene (IC$_{50}$ = 7.4 ± 0.5 µmol L$^{–1}$, SI = 5.8) exert remarkable activity and selectivity against human malignant glioblastoma cell line (U251) in vitro. On the other hand, amide-type harmicens 10, 12, and 14 exhibited strong, but non-selective activity, in the low micro-molar range. Mechanistic studies revealed that among active compounds, amide-type harmicens 12 and 14 inhibit DYRK1A and Hsp90 CTD, whereas compound 14 showed pronounced antioxidative activity. Therefore, the antiproliferative activity of harmicens might be a combination of complex molecular interactions.</dc:description><dc:date>2024</dc:date><dc:date>2025-01-21 08:22:39</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>166656</dc:identifier><dc:identifier>UDK: 616-006.48</dc:identifier><dc:identifier>ISSN pri članku: 1846-9558</dc:identifier><dc:identifier>DOI: 10.2478/acph-2024-0033</dc:identifier><dc:identifier>COBISS_ID: 206354179</dc:identifier><dc:language>sl</dc:language></metadata>
